U.S. markets closed

Biofrontera AG (BFRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.94-0.50 (-7.76%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close6.44
Bid5.55 x 2900
Ask5.90 x 800
Day's Range5.51 - 6.01
52 Week Range4.67 - 55.00
Avg. Volume94,041
Market Cap164.919M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Biofrontera Raises $8.9M Via Equity Offering

    Biofrontera AG (NASDAQ: BFRA) priced an underwritten public offering of around 1.3 million ADS at $6.68 per ADS, raising gross proceeds of approximately $8.9 million. The offer price represents a discount of 5% from the last close price of $7.04 on Tuesday. Each ADS represents two of BFRA's ordinary shares. The offering will close by February 26. This offer is part of concurrent preemptive rights offered to the company's ordinary shares holders of around 8.9 million ordinary shares at €2.75 per share. Proceeds will be used for regulatory approval for expanded use of its lead product Ameluz, in the U.S. to basal cell carcinoma, acne, and actinic keratoses, complete the development of a larger BF-RhodoLED lamp, and for general corporate purposes. The Benchmark Company is acting as the managing underwriter with Lake Street Capital Markets acting as co-manager for the offering. Price Action: BFRA is down 1.6% at $6.91 in premarket trading on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaICON Scoops Up PRA Health Sciences In B DealKaryopharm's Partner Antengene Receives Priority Review For Selinexor Application In China© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Benzinga

    Biofrontera: Q3 Earnings Insights

    Shares of Biofrontera (NASDAQ:BFRA) moved higher by 0.1% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share were flat 0.00% year over year to ($0.00), which beat the estimate of ($0.34).Revenue of $5,508,000 declined by 1.98% from the same period last year, which missed the estimate of $5,900,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.View more earnings on BFRABiofrontera hasn't issued any revenue guidance for the time being.Recent Stock Performance Company's 52-week high was at $55.00Company's 52-week low was at $5.27Price action over last quarter: down 32.85%Company Profile Biofrontera AG is active in the field of healthcare in the United Kingdom. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 11, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Biofrontera AG (BFRA) Q2 2020 Earnings Call Transcript
    Motley Fool

    Biofrontera AG (BFRA) Q2 2020 Earnings Call Transcript

    May I now hand you over to Pamela Keck, Head of Investor Relations, who will lead you for this conference. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.